Vericiguat
FDA-approved product (tablet, oral), marketed as Verquvo.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Heart failure
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other vasodilators used in cardiac diseases
- FDA pharmacologic class
- Soluble Guanylate Cyclase Stimulator FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Vericiguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients
NCT02617550 · start 2015-11-18
Registered record
- Registry ID
- NCT02617550
- Conditions
- Coronary Artery Disease
- Interventions
- Vericiguat (BAY1021189); Placebo; Nitroglycerin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-11-18
- Completion
- 2016-08-11
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionVericiguat (BAY1021189); Placebo; NitroglycerinPhasePhase 1Registry statusCompletedA Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
NCT04722562 · start 2014-07-16
Registered record
- Registry ID
- NCT04722562
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-07-16
- Completion
- 2015-04-30
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart FailureInterventionVericiguat (BAY1021189)PhasePhase 1Registry statusCompletedA Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
NCT04722484 · start 2014-06-12
Registered record
- Registry ID
- NCT04722484
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-06-12
- Completion
- 2015-01-22
- Enrolment
- 39
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart FailureInterventionVericiguat (BAY1021189)PhasePhase 1Registry statusCompletedPhase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
NCT01951625 · start 2013-11-29
Registered record
- Registry ID
- NCT01951625
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg); Vericiguat (BAY1021189) (5 mg); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-11-29
- Completion
- 2015-06-09
- Enrolment
- 456
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart FailureInterventionVericiguat (BAY1021189) (1.25 mg); Vericiguat (BAY1021189) (5 mg); PlaceboPhasePhase 2Registry statusCompletedPhase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
NCT01951638 · start 2013-11-06
Registered record
- Registry ID
- NCT01951638
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg); Vericiguat (BAY1021189) (5 mg); Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2013-11-06
- Completion
- 2015-09-16
- Enrolment
- 477
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart FailureInterventionVericiguat (BAY1021189) (1.25 mg); Vericiguat (BAY1021189) (5 mg); PlaceboPhasePhase 2Registry statusCompleted